HCW Biologics Inc. (NASDAQ:HCWB) stock is up on Friday, as traders reacted to a fresh capital injection. The surge follows a massive 262% rally earlier in the month, driven by strong first-quarter financial results and an exclusive worldwide licensing agreement with Trimmune.
• HCW Biologics stock is showing exceptional strength. What’s fueling HCWB momentum?
Something went wrong.
Private Placement Pricing Details
According to the company’s Form 8-K filed with the U.S. Securities and Exchange Commission on Thursday, the clinical-stage biopharmaceutical firm entered into a Securities Purchase Agreement with accredited health care investors. The company priced the private placement offering to raise approximately $4 million by issuing an aggregate of 2,846,975 units at a purchase price of $1.405 per unit.
